<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04058210</url>
  </required_header>
  <id_info>
    <org_study_id>VX18-445-901</org_study_id>
    <nct_id>NCT04058210</nct_id>
  </id_info>
  <brief_title>VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)</brief_title>
  <official_title>VX-445/TEZ/IVA Triple Combination Expanded Access Program for Patients 12 Years of Age and Older With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function CFTR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <brief_summary>
    <textblock>
      The purpose of this program is to provide elexacaftor(ELX,
      VX-445)/tezacaftor(TEZ)/ivacaftor(IVA) combination therapy to CF patients in critical need
      who are 12 years of age and older, heterozygous for F508del and a minimal function (MF)
      mutation in response to unsolicited physician requests.
    </textblock>
  </brief_summary>
  <overall_status>Approved for marketing</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELX/TEZ/IVA</intervention_name>
    <description>Fixed-dose combination tablet for oral administration.</description>
    <other_name>elexacaftor/tezacaftor/ivacaftor</other_name>
    <other_name>VX-445/VX-661/VX-770</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IVA</intervention_name>
    <description>150-mg tablet for oral administration.</description>
    <other_name>ivacaftor</other_name>
    <other_name>VX-770</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Patients who have F/MF genotypes AND who meet at least 1 of the following criteria:

          -  The percent predicted forced expiratory volume in 1 second (ppFEV1) is &lt;40 for a
             minimum of 2 months before the date of the request, OR

          -  Documentation of being active on a lung transplant waiting list or documentation of
             being evaluated for lung transplantation, but deemed unsuitable because of
             contraindications

        Exclusion Criteria:

          1. Patients with severe hepatic impairment (Child-Pugh Class C)

          2. History of any other comorbidity that, in the opinion of the treating physician, might
             pose undue risk in administering ELX/TEZ/IVA to the patient

          3. Pregnancy

        Other protocol defined Inclusion/Exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

